We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Toxoplasmosis Immune Status in Pregnancy Determined by Immunochromatography Assay

By LabMedica International staff writers
Posted on 30 Mar 2021
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite, one of the world's most common parasites. More...
Infection usually occurs by eating undercooked contaminated meat, exposure from infected cat feces, or mother-to-child transmission during pregnancy.

Obstetrical toxoplasmosis involves the systematic serological screening for Toxoplasma‐specific IgG and IgM antibodies which is usually performed using enzyme-linked immunosorbent assay (ELISA) techniques. Screening tests used routinely are not sufficient and require additional techniques to determine the Toxoplasma immune status.

Medical Parasitologists at the Pasteur Institute of Tunis (Tunis, Tunisia) selected 39 sera collected during the period 2015 to 2018 in the setting of the routine Toxoplasma serological screening in pregnant women. Sera were selected according to their anti‐Toxoplasma IgM and IgG antibodies titers in “Platelia Toxo IgG, IgM” (Bio-Rad, Marnes-la-Coquette, France).

Western blot Toxo II IgG (LDBIO DIAGNOSTICS, Lyon, France) was performed for all the sera in order to precisely determine their exact Toxoplasma immune status. The LDBIO Toxoplasma ICT IgG‐IgM is a rapid, simple, qualitative test based on immunochromatography technology (ICT, lateral flow). A positive test reveals the presence of anti‐Toxoplasma antibodies, but does not distinguish between IgG and IgM classes.

The scientists reported that in the absence of IgM and presence of IgG equivocal titers in ELISA, Toxoplasma ICT IgG‐IgM and WB Toxo II results were 94.7% concordant. All positive samples in WB were also positive in ICT. The sensitivity in the detection either of low IgG titers in absence of IgM or of specific anti‐Toxoplasma IgM was 100%. Only one serum with equivocal IgG titer by ELISA and negative with Toxo II IgG test revealed positive in ICT. However, this serum showed a P30 band in WB analysis. On the other hand, three sera positive in ELISA IgM and negative in ELISA IgG revealed positive in ICT and negative in WB Toxo II IgG, the reference test.

The authors concluded that their results confirm the high sensitivity of Toxoplasma ICT IgG‐IgM in detecting both specific anti‐Toxoplasma IgG and IgM, and highlight the usefulness of this rapid test as a first or second‐line Toxoplasma serological test in pregnant women. The study was published on March 15, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Pasteur Institute of Tunis
Bio-Rad
LDBIO DIAGNOSTICS



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: The proposed workflow adds liquid biopsy to detect genetic and molecular signs of cancer in CSF samples already collected during autoimmune encephalitis evaluation. (Image Credit: Shutterstock)

CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation

Autoimmune encephalitis can cause memory and behavioral changes, seizures, and altered consciousness, but diagnosis can be challenging because cancers involving the brain and central nervous system may... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.